Journals / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 7

Expression level of UCMA as a candidate molecular targetin osteoarthritis

Pages
1417–1422
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our study, as the first one using the human osteoblast cell line, provides good evidence about the potential value of UCMA in the pathophysiology of OA and shows that UCMA can be a promising molecular target to develop therapeutic approaches for OA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Osteoarthritis (OA) is a degenerative joint disorder that damages cartilage, synovium and subchondral bone, and there is yet no effective treatment for OA.
📊
Key Findings & Data:Upper zone of growth plate and cartilage matrix associated (UCMA) was discovered as a chondrocyte specific protein in 2008, but its expression is solely not specific to cartilage tissue.
💡
Conclusion & Impact:Conclusion: Our study, as the first one using the human osteoblast cell line, provides good evidence about the potential value of UCMA in the pathophysiology of OA and shows that UCMA can be a promising molecular target to develop therapeutic approaches for OA.
🔬Design:Modeling & Simulation
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Osteoarthritis (OA) is a degenerative joint disorder that damages cartilage, synovium and subchondral bone, and there is yet no effective treatment for OA. The identification of novel therapeutic methods is crucially needed for better treatment of OA. Upper zone of growth plate and cartilage matrix associated (UCMA) was discovered as a chondrocyte specific protein in 2008, but its expression is solely not specific to cartilage tissue. Although UCMA is implicated in cartilage and bone metabolic processes, the molecular function of UCMA in OA is not elucidated yet. We aimed to examine the potential effect of UCMA in osteoblast metabolism associated with OA. Materials and Methods: We created an in vitro OA model by inducing osteoblast cell line with IL-1β. The expression levels of 12 related genes were determined using the qRT-PCR method. The MMP1 and OPG expression levels in the supernatants of cells were detected with ELISA. Results: We found that there was a dramatic increase in the levels of UCMA expression and other OA-related markers. We showed that IL-1β triggered the expression of main transcription factors playing a role during bone formation. MMP1 and OPG synthesis and secretions were increased in IL-1β induced-hFOB1.19 cell line significantly. Conclusion: Our study, as the first one using the human osteoblast cell line, provides good evidence about the potential value of UCMA in the pathophysiology of OA and shows that UCMA can be a promising molecular target to develop therapeutic approaches for OA.

🔖

Cite This Article

OKUYAN, H. M., SÖNMEZ, D., ARSLAN, A., IĞCI, Y. Z., GÖĞEBAKAR, B., BİLGİÇ, N., GÜNDÜZ, K. (2022). Expression level of UCMA as a candidate molecular targetin osteoarthritis. Annals of Medical Research, Cilt: 28 - Sayı: 7, 1417–1422. https://ajindex.com/articles/446269

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Hosnijeh FS, Runhaar J, van Meurs JB, et al. Biomarkers for osteoarthritis: Can they be used for risk assessment? A systematic review. Maturitas 2015;82:36-49
  2. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone 2012;51:249-57
  3. Kirwan JR, Elson CJ. Is the progression of osteoarthritis phasic? Evidence and implications. J Rheumatol 2000;27:834-6
  4. Kraus VB, Blanco FJ, Englund M, et al. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis Cartilage 2015;23:1233-41
  5. Kwan Tat S, Lajeunesse D, Pelletier JP, et al. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 2010;24:51-70
  6. Findlay DM, Atkins GJ. Osteoblast-chondrocyte interactions in osteoarthritis. Curr Osteoporos Rep 2014;12:127-34
  7. Maruotti N, Corrado A, Cantatore FP. Osteoblast role in osteoarthritis pathogenesis. J Cell Physiol 2017;232:2957-63
  8. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002;30:340-6
  9. Kwan Tat S, Pelletier JP, Lajeunesse D, et al. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol 2008;26:295- 304
  10. Rigoglou S, Papavassiliou AG. The NF-kappaB signalling pathway in osteoarthritis. Int J Biochem Cell Biol 2013;45:2580-4
  11. Kwan Tat S, Padrines M, Theoleyre S, et al. IL6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004;15:49-60
  12. Price PA, Williamson MK, Haba T, et al. Excessive mineralization with growth plate closure in rats on chronic warfarin treatment. Proc Natl Acad Sci U S A 1982;79:7734-8
  13. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78-81
  14. Neacsu CD, Grosch M, Tejada M, et al. Ucmaa (Grp2) is required for zebrafish skeletal development. Evidence for a functional role of its glutamate gammacarboxylation. Matrix Biol 2011;30:369-78
  15. Misra D, Booth SL, Tolstykh I, et al. Vitamin K deficiency is associated with incident knee osteoarthritis. Am J Med 2013;126:243-8
  16. Cancela ML, Conceicao N, Laize V.